Pharma plant sales and regulatory consultancy in India

The three units featured above run from ₹11 crore for a running oral-solid and semi-solid unit to ₹50 crore for a sterile injectable facility. Across the full list of eighteen the range is wider at both ends.

The spread is driven far more by dosage form and certificate scope than by floor area. A sterile facility carries cleanroom infrastructure, HVAC validation and qualification history that an oral-solid unit simply does not, and that is where the money sits. Land value in Baddi, Roorkee or Paonta Sahib is usually the smaller half of the number.

Not automatically. A manufacturing licence is granted to a named applicant, for named premises and named sections — so buying the building and the machinery does not by itself put the licence in your hands.

In practice a transaction is structured one of two ways. In an asset purchase, you apply to the state licensing authority for your own licence at those premises. In a share or entity purchase, the licence-holding company continues to exist and you acquire it — which keeps the licence and its approval history intact, but brings the company's liabilities with it.

Where we come in: we handle the regulatory side of the transfer — preparing the applications and assembling the supporting documentation the licensing authority will ask for.

Which route suits you depends on what you are actually buying: the sections, the approval history, or the customer contracts. Practice also varies between state licensing authorities, so the position should be confirmed with the specific authority before the structure is fixed.

No, and this is the single most common misreading we see. A WHO-GMP certificate is issued for specific sections and products, not for a building. A unit can be entirely genuine in describing itself as WHO-GMP certified while half its licensed sections sit outside that certificate.

One of the units currently listed is exactly this case: it is licensed for tablets, capsules, liquid orals and dry syrup, but the WHO-GMP certificate covers tablets and capsules only. If your plan is to export liquid orals from that plant, the certificate does not help you and the section would need to be brought into scope. That is why our listings state the scope rather than the badge.

It means the compliance gap is now yours to close, and the grace period is gone. Revised Schedule M took effect on 1 January 2025. Notification G.S.R. 127(E) of 11 February 2025 allowed manufacturers with turnover below ₹250 crore until 31 December 2025, but only if they applied to the Central Licence Approving Authority within three months with an upgradation plan.

Of roughly 8,500 MSME units in India, only about 1,600 to 1,700 applied. In a directive dated 7 November 2025 the DCGI asked state licensing authorities to plan inspections with compliance verification from 1 January 2026 and to report monthly.

For a buyer this converts Schedule M from a paperwork item into a valuation item. A unit that neither complied nor applied is exposed to inspection now, and the cost of bringing it into compliance belongs in your offer, not in a surprise six months after closing. Our Schedule M dashboard tracks where enforcement currently stands.

Buy when you need approved sections and an inspection history quickly, and you have the capital. You are paying a premium for time and for a licence that already exists.

Build when your product mix does not match anything available, or when you want a facility designed to Revised Schedule M from the foundation rather than retrofitted to it. Slower, and the licensing timeline is the long pole. Our setup cost calculator will give you an indicative capital figure.

Rent when you need a first commercial batch before you need an asset. A Revised Schedule M compliant unit taken on rent removes the capital question entirely and lets you prove the market first — see units available on rent.

Nothing that identifies your unit is published. Listings carry the district, the approved sections and the specifications — never the company name, never photographs of the premises, never anything a competitor or a customer could match to you.

Identity is disclosed to a buyer only after a non-disclosure agreement is in place and we are satisfied the enquiry is genuine. A running plant cannot afford its staff, its customers or its regulators learning it is for sale from a website, and that constraint shapes how the whole process is run.

We read the licence and the sections named on it, and the certificate and what it actually covers. Where a section is licensed but sits outside a certificate, we say so on the listing rather than leaving you to discover it in diligence — the Baddi unit above is exactly that case.

Specifications, pricing and availability are as supplied by the seller. This is a documentary review, not an independent audit or a valuation, and it is not a substitute for your own technical, financial and legal due diligence. We do not verify title, encumbrances or financial records. The acquisition checklist sets out what belongs on your side.

Brokerage is charged as a percentage of deal value: 2% on deals up to ₹5 crore, and 1.5% on deals above ₹5 crore. The rate above the threshold applies to the full deal value, not only to the amount above it.

Requirement analysis and an initial shortlist carry no charge.